3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
4
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
40
Neoplasms
4
Triple Negative Breast Neoplasms
3
Obesity
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Kidney Neoplasms
2
Insulin Resistance
2
Colonic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Carcinoma In Situ
2
Breast Cancer Female
2
Brain Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sleep Wake Disorders
1
Sezary Syndrome
1
Rectal Neoplasms
1
Racism
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peripheral Nervous System Diseases
1
Interventions
pembrolizumab
24
Nivolumab
7
Early Intervention, Educational
7
Methods
6
durvalumab
5
aldesleukin
5
Trastuzumab
5
Paclitaxel
5
Fulvestrant
5
Carboplatin
5
atezolizumab
4
Surveys and Questionnaires
4
Patient Navigation
4
Docetaxel
4
Cyclophosphamide
4
Biopsy
4
fludarabine
3
Mass Screening
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Interleukin-2
3
Gene Expression Profiling
3
Fluorouracil
3
Educational Status
3
Bevacizumab
3
tremelimumab
2
spartalizumab
2
sargramostim
2
palbociclib
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Metformin
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled